HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment
NCT ID: NCT04613297
Last Updated: 2022-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
91 participants
INTERVENTIONAL
2020-10-19
2022-07-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Precision Immunology to Determine the Immune Response in Patients With COVID-19
NCT04360733
Development and Qualification of Methods for Analyzing the Mucosal Immune Response to COVID-19
NCT06142279
Pandemic Triage Score in Patients With Known or Suspected Severe Acute Respiratory Syndrome (SARS) CoronaVirus (CoV) 2 Infection
NCT04371471
Understanding COVID-19
NCT04329546
Immunological Profiling of Patients With COVID-19 in Respiratory Distress
NCT04351711
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COVID-19 uninfected patients
Patient with negative PCR result
Baseline blood sample
Blood sample will be performed at the inclusion visit only
non-hospitalized COVID-19 infected patients
Patient with positive PCR result who does not require hospitalization for COVID-19
Baseline blood sample
Blood sample will be performed at the inclusion visit only
hospitalized COVID-19 infected patients
Patient with positive PCR who require hospitalization for COVID-19
Baseline and during hospitalization blood samples
Blood sample will be performed at the inclusion visit for all patient and for the hospitalized COVID-19 infected patients, extra-blood samples will be performed :
* at day 3
* day 5 and
* In case of aggravation
* At the discharge from hospital
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Baseline and during hospitalization blood samples
Blood sample will be performed at the inclusion visit for all patient and for the hospitalized COVID-19 infected patients, extra-blood samples will be performed :
* at day 3
* day 5 and
* In case of aggravation
* At the discharge from hospital
Baseline blood sample
Blood sample will be performed at the inclusion visit only
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hopital Foch
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Olivier BRUGIERE, PhD
Role: PRINCIPAL_INVESTIGATOR
Hopital Foch
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Foch hospital
Suresnes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020_0082
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.